Drug
Regn7508
Regn7508: highest development phase Phase 3, developed by Regeneron. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN7508 NCT07430956 | Phase 3 | Atrial Fibrillation (AF) |
| REGN7508 NCT07493304 | Phase 3 | Venous Thromboembolism (VTE) |
| REGN7508 NCT07410117 | Phase 3 | Cancer-Associated Thrombosis (CAT) |
| REGN7508 NCT07318610 | Phase 3 | Peripheral Artery Disease (PAD) |
| REGN7508 NCT07015905 | Phase 3 | Venous Thromboembolism (VTE) |
| REGN7508 NCT07175428 | Phase 2 | Atrial Fibrillation (AF) |
Latest
No recent events.
Follow Regn7508 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.